309 related articles for article (PubMed ID: 35784359)
41. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
Nielsen BU; Drabe CH; Barnkob MB; Johansen IS; Hansen AKK; Nilsson AC; Rasmussen LD
Front Immunol; 2022; 13():934476. PubMed ID: 35967433
[TBL] [Abstract][Full Text] [Related]
42. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
43. Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients.
Barrios Y; Franco A; Alava-Cruz C; Cuesta-Martin R; Camara C; Matheu V
Allergol Immunopathol (Madr); 2022; 50(3):101-105. PubMed ID: 35527662
[TBL] [Abstract][Full Text] [Related]
44. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
Quinti I; Locatelli F; Carsetti R
Front Immunol; 2021; 12():815404. PubMed ID: 35126372
[TBL] [Abstract][Full Text] [Related]
45. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
46. SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine.
Gupta S; Agrawal S; Sandoval A; Su H; Tran M; Demirdag Y
J Clin Immunol; 2022 Jul; 42(5):914-922. PubMed ID: 35366743
[TBL] [Abstract][Full Text] [Related]
47. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
Azamor T; Horbach IS; Brito E Cunha D; Melgaço JG; Silva AMVD; Tubarão LN; Azevedo AS; Santos RT; Alves NDS; Machado TL; Silva J; Souza AF; Bayma C; Rocha VP; Frederico ABT; Dias BM; Setatino BP; Denani CB; Campos SPDC; Schwarcz WD; Sucupira MV; Mendes EP; Silva EDD; Barbosa de Lima SM; Ano Bom APD; Missailidis S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146723
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
49. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
50. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Four T-cell Assays and Two Binding Antibody Assays in SARS-CoV-2 Vaccinees With or Without Omicron Breakthrough Infection.
Seo YJ; Oh I; Nam M; Shin S; Roh EY; Song EY
Ann Lab Med; 2023 Nov; 43(6):596-604. PubMed ID: 37387492
[TBL] [Abstract][Full Text] [Related]
52. Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions.
Capuano C; De Federicis D; Ciuti D; Turriziani O; Angeloni A; Anastasi E; Giannini G; Belardinilli F; Molfetta R; Alvaro D; Palmieri G; Galandrini R
Front Immunol; 2023; 14():1285203. PubMed ID: 38045702
[TBL] [Abstract][Full Text] [Related]
53. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
54. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E; Goodyear CS; Willicombe M; Gaskell C; Siebert S; I de Silva T; Murray SM; Rea D; Snowden JA; Carroll M; Pirrie S; Bowden SJ; Dunachie SJ; Richter A; Lim Z; Satsangi J; Cook G; Pope A; Hughes A; Harrison M; Lim SH; Miller P; Klenerman P; ; Basu N; Gilmour A; Irwin S; Meacham G; Marjot T; Dimitriadis S; Kelleher P; Prendecki M; Clarke C; Mortimer P; McIntyre S; Selby R; Meardon N; Nguyen D; Tipton T; Longet S; Laidlaw S; Orchard K; Ireland G; ; Thomas D; Kearns P; Kirkham A; McInnes IB;
Nat Med; 2023 Jul; 29(7):1760-1774. PubMed ID: 37414897
[TBL] [Abstract][Full Text] [Related]
56. Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic.
Costanzo GAML; Deiana CM; Sanna G; Perra A; Campagna M; Ledda AG; Coghe F; Palmas V; Cappai R; Manzin A; Chessa L; Del Giacco S; Firinu D
J Clin Immunol; 2023 Dec; 44(1):12. PubMed ID: 38129351
[TBL] [Abstract][Full Text] [Related]
57. Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.
Rosenthal JA; Papa MP; Sanz M; Nicholes S; Holmberg CS; Bosque A; Keswani A; Amdur R; Lynch RM; Soriano-Sarabia N; Ein D
Ann Allergy Asthma Immunol; 2023 Jun; 130(6):743-751.e3. PubMed ID: 36736722
[TBL] [Abstract][Full Text] [Related]
58. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
[TBL] [Abstract][Full Text] [Related]
59. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
60. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
Front Immunol; 2022; 13():975363. PubMed ID: 36119092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
